Digiceuticals: The Future of Healthcare with Pharmacist and Physician Guidance

Digiceuticals, also known as digital therapeutics, are rapidly transforming healthcare. These software-based interventions offer new ways to prevent, manage, and treat medical conditions. This article explores the world of digiceuticals, their benefits, challenges, and the essential roles pharmacists and physicians play in their integration into patient care.

Image credit: Sergey Nivens | stock.adobe.com

What are Digiceuticals?

The Digital Therapeutics Alliance defines digiceuticals as evidence-based therapeutic interventions driven by software to prevent, manage, or treat medical disorders or diseases. They are distinct from broader categories like digital health (e.g., electronic medical records, fitness trackers) and digital medicine (e.g., digital diagnostics, ingestible sensors). Digiceuticals deliver targeted treatments, similar to pharmaceuticals, but through digital means.

FDA Regulation and Classification

In the United States, the FDA regulates digiceuticals as medical devices under the Center for Devices and Radiological Health. They are classified into Class I, II, or III based on risk, with Class III posing the highest potential harm. The FDA’s Pre-Cert Pilot Program aims to streamline the approval process for digital health technologies, ensuring safe and effective products reach patients faster.

The Growing Digiceutical Market

Several factors contribute to the rise of digiceuticals, including the increasing prevalence of chronic diseases, a shift towards preventative medicine, and the demand for personalized care. The global market for digital therapeutics is projected to reach $12.1 billion by 2026.

Examples of Digiceuticals

Current digiceuticals address various conditions. Propeller, for instance, helps manage respiratory diseases like asthma and COPD by tracking medication use through a smartphone-connected inhaler sensor. Nerivio, a neuromodulation device worn on the upper arm, offers migraine relief through a smartphone-controlled app. Rejoyn, a recently FDA-cleared digiceutical, is the first approved for treating major depressive disorder.

📚 Unlock the World of AI and Humanity with These Two Free Books! 🚀

Dive into the thrilling realms of artificial intelligence and humanity with "The ECHO Conundrum" and "Awakening: Machines Dream of Being Human". These thought-provoking novels are FREE this week! Don't miss the chance to explore stories that challenge the boundaries of technology and what it means to be human.

Read More & Download

The Role of Pharmacists and Physicians

Pharmacists play a crucial role in verifying prescriptions for digiceuticals, ensuring appropriate indication, patient suitability, dosage, and timing. They also evaluate the clinical significance of these products, analyze relevant literature, and monitor patient response to therapy. In outpatient settings, pharmacists provide ongoing assessment and support.

Physicians, with their broad medical knowledge, diagnose conditions and prescribe appropriate treatments, including digiceuticals. They integrate these digital tools into comprehensive treatment plans, considering patient history, lifestyle, and other medications. Collaboration between pharmacists and physicians ensures safe and effective digiceutical implementation.

Benefits and Challenges of Digiceuticals

Digiceuticals offer several advantages, including fewer side effects compared to traditional medications, continuous monitoring capabilities, and enhanced patient engagement in their care.

However, challenges exist. Cybersecurity and data privacy are major concerns with software-driven interventions. Technology failures and lack of access to technology for some patients pose additional hurdles. Resistance to adopting new technologies and the affordability of digiceuticals require ongoing attention.

The Future of Digiceuticals

Specialty pharmacies and ambulatory care settings are likely to be key players in promoting and assessing digiceuticals. Patient assistance programs and prior authorizations will be important for access. Educational sessions will promote understanding and adoption of these new therapies. The integration of digiceuticals with artificial intelligence holds tremendous potential for personalized and predictive healthcare.

Conclusion

Digiceuticals offer exciting possibilities for improving healthcare. While challenges remain, ongoing development, collaboration among healthcare professionals, and patient education will pave the way for wider adoption and realization of the full potential of these innovative digital therapies. For personalized treatment plans incorporating digiceuticals, consult with a healthcare professional.

References

1. Wang C, Lee C, Shin H. Digital Therapeutics from bench to bedside. npj Digital Medicine. 2023;6(1).
2. United States Regulatory. Accessed May 14, 2024.
3. About DTA – Digital Therapeutics Alliance. Digital Therapeutics Alliance. April 22, 2024.
4. Digital Health Industry Categorization. Accessed May 14, 2024.
5. Defining digital medicine. Digital Medicine Society (DiMe). March 5, 2024.
6. Watson A, Chapman R, Shafai G, Maricich YA. FDA regulations and Prescription Digital Therapeutics: Evolving with the technologies they regulate. Frontiers in Digital Health. 2023;5.
7. Center for Devices and Radiological Health. Classify your medical device. U.S. Food and Drug Administration. Accessed May 13, 2024.
8. Digiceuticals market. Future Market Insights. March 13, 2023.
9. Batta A, Khirasaria R, Singh V. Exploring digital therapeutics: The next paradigm of modern health-care industry. Perspectives in Clinical Research. 2020;11(2):54.
10. Watson A, Chapman R, Shafai G, Maricich YA. FDA regulations and Prescription Digital Therapeutics: Evolving with the technologies they regulate. Frontiers in Digital Health. 2023;5.
11. Propeller® – Digital Therapeutics Alliance. Digital Therapeutics Alliance. February 2, 2024.
12. Yawn BP, McCreary GM, Linnell JA, et al. Pilot study of a patient experience with an ELLIPTA inhaler electronic medication monitor and associated integrated system: A prospective observational study using the COPD patient-powered research network. Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation. 2021;8(4):488-501.
13. Nerivio® – Digital therapeutics alliance. Digital Therapeutics Alliance. February 2, 2024.
14. Grosberg B, Rabany L, Lin T, et al. Safety and efficacy of remote electrical neuromodulation for the acute treatment of chronic migraine: An open-label study. PAIN Reports. 2021;6(4).
15. Ailani J, Burch RC, Robbins MS. The American Headache Society Consensus statement: Update on integrating new migraine treatments into clinical practice. Headache: The Journal of Head and Face Pain. 2021;61(7):1021-1039.
16. Announcing the first and only prescription app for the treatment of depression symptoms. A prescription app you can add to your antidepressant. Accessed May 13, 2024.
17. D. Aungst T, Franzese C, Kim Y. Digital Health Implications for Clinical Pharmacists Services: A Primer on the current landscape and future concerns. JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY. 2020;4(4):514-524.
18. Shafai G, Aungst TD. Prescription digital therapeutics: A new frontier for pharmacists and the future of treatment. Journal of the American Pharmacists Association. 2023;63(4):1030-1034.
19. 10 November 2023 By Ashifa Trivedi & Sarah Mohamad. Digital Therapeutics: Integration in practice. The Pharmaceutical Journal. November 10, 2023.
20. Digiceuticals market 2024-2032: Size,share, growth. MarkWide Research. April 11, 2024.